F-star Therapeutics’s Return On Capital Employed Insights
According to Benzinga Pro, during Q4, F-star Therapeutics (NASDAQ:FSTX) earned $4.74 million, a 143.93% increase from the preceding quarter. F-star Therapeutics also posted a total of $17.50 million in sales, a 2230.09% increase since Q3.
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's session, 454 stocks hit new 52-week lows.
Earnings Scheduled For March 14, 2022
Companies Reporting Before The Bell
• F45 Training Holdings (NYSE:FXLV) is projected to report earnings for its fourth quarter.
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb’s Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments served as catalysts during the week.
F-star Announces Issuance Of US Patent Protecting FS118, A Bispecific Antibody Targeting PD-L1 And LAG-3
Provides U.S. Patent Protection to at least August 2038
Expands Patent Protection for FS118 Composition of Matter beyond Europe
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) -- F-star
Peering Into F-star Therapeutics Recent Short Interest
F-star Therapeutics Inc. - Common Stock's (NASDAQ:FSTX) short percent of float has fallen 90.16% since last its last report. The company recently reported that it has 108.00 thousand shares sold short, which is 0.67% of all regular shares that are available for trading.
Earnings Scheduled For November 10, 2021
Companies Reporting Before The Bell
• LumiraDx (NASDAQ:LMDX) is projected to report quarterly loss at $0.24 per share on revenue of $94.32 million.